According to NIAID Director Anthony S. Fauci, M.D., “We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment. Although there is anecdotal evidence that hydroxychloroquine (HCQ) and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes.”
To learn more, the National Institute of Health (NIH) is beginning a clinical trial that hopes to understand whether HCQ and azithromycin truly are effective or if the treatment is no better than a placebo. This study is also aimed at determining what risks are involved when treating COVID-19 patients with these medications.